Glutamine antagonists may KEAP lung cancer in check

Authors: Eliot B. Blatt, Ralph J. DeBerardinis

Published: 2024-03-27

DOI: 10.1126/sciadv.ado7808

Source: Full article

---

Abstract

The glutamine antagonist DRP-104 blocks purine synthesis and combines with checkpoint inhibitors to promote antitumor immunity in KEAP1/NRF2-mutant lung cancers.